Winrevair (sotatercept-csrk), compared to placebo, reduced the risk of all-cause death, lung transplantation, and hospitalization.

Ulcerative colitis (UC) is one of the most severe chronic diseases, causing relentless gastrointestinal pain and ...

Shanghai Ark Biopharmaceutical Co., Ltd. ('ArkBio') today announced the successful completion of the Phase III clinical study ...

BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated macrophages (TAMs). This single-agent, dose-escalation Phase 1 clinical ...